Rituximab and Abatacept for Prevention or Reversal of Type 1 Diabetes
Status:
Suspended
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
The study is a clinical trial testing sequential therapy with rituximab followed by abatacept
in individuals destined to develop clinical type 1 diabetes.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborators:
Juvenile Diabetes Research Foundation National Institutes of Health (NIH)